Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Dec 29, 2023 (filed on Dec 29, 2023)Insider Name:Trombly Amy MossOwnership Type:Direct OwnershipSecurities:Stock option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:60,000Price:--
-
Dec 29, 2023 (filed on Dec 29, 2023)Insider Name:Thornton BruceOwnership Type:Direct OwnershipSecurities:Stock option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:60,000Price:--
-
Dec 29, 2023 (filed on Dec 29, 2023)Insider Name:Dal Poggetto JohnOwnership Type:Direct OwnershipSecurities:Stock option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:50,000Price:--
-
Dec 29, 2023 (filed on Dec 29, 2023)Insider Name:Dvonch Jerome JOwnership Type:Direct OwnershipSecurities:Stock option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:60,000Price:--
-
Jul 21, 2023 (filed on Jul 21, 2023)Insider Name:Dal Poggetto JohnOwnership Type:Direct OwnershipSecurities:Stock option (right to buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Jun 30, 2023 (filed on Jul 03, 2023)Insider Name:Trombly Amy MossOwnership Type:Direct OwnershipSecurities:Common Stock, $0.0001 par valueNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:100,000Price:--
-
Jun 30, 2023 (filed on Jul 03, 2023)Insider Name:Thornton BruceOwnership Type:Direct OwnershipSecurities:Common Stock, $0.0001 par valueNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:100,000Price:--
Filings by filing date
-
Dec 29, 2023 (filed on Dec 29, 2023)Insider Name:Trombly Amy MossOwnership Type:Direct OwnershipSecurities:Stock option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:60,000Price:--
-
Dec 29, 2023 (filed on Dec 29, 2023)Insider Name:Thornton BruceOwnership Type:Direct OwnershipSecurities:Stock option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:60,000Price:--
-
Dec 29, 2023 (filed on Dec 29, 2023)Insider Name:Dal Poggetto JohnOwnership Type:Direct OwnershipSecurities:Stock option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:50,000Price:--
-
Dec 29, 2023 (filed on Dec 29, 2023)Insider Name:Dvonch Jerome JOwnership Type:Direct OwnershipSecurities:Stock option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:60,000Price:--
-
Jul 21, 2023 (filed on Jul 21, 2023)Insider Name:Dal Poggetto JohnOwnership Type:Direct OwnershipSecurities:Stock option (right to buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Jun 30, 2023 (filed on Jul 03, 2023)Insider Name:Trombly Amy MossOwnership Type:Direct OwnershipSecurities:Common Stock, $0.0001 par valueNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:100,000Price:--
-
Jun 30, 2023 (filed on Jul 03, 2023)Insider Name:Thornton BruceOwnership Type:Direct OwnershipSecurities:Common Stock, $0.0001 par valueNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:100,000Price:--
News
Biz Brief
Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 5445 CONESTOGA COURT, SUITE 150 BOULDER CO 80301 |
Tel: | N/A |
Website: | https://sonomapharma.com |
IR: | See website |
Key People | ||
Amy Trombly Chief Executive Officer, Director | Jerry Dvonch Interim Chief Financial Officer | Bruce Thornton Chief Operating Officer, Corporate Secretary | John Dal Poggetto Controller |
Business Overview |
Sonoma Pharmaceuticals, Inc. is engaged in developing and producing stabilized hypochlorous acid (HOCl), products for a range of applications, including wound care, animal health care, eye care, oral care and dermatological conditions. The Company's product offerings include Regenacyn Advanced Scar Gel, Regenacyn Plus Scar Gel, Rejuvacyn Advanced Skin Repair Cooling Mist, Pediacyn Skin Care, Microcyn, Ocucyn Eyelid and Eyelash Cleanser, Microdacyn60 Oral Care, Podiacyn Advanced Everyday Foot Care, and MicrocynAH. Regenacyn Advanced Scar Gel helps to improve the overall appearance of scars while reducing pain, itch, redness, and inflammation. Regenacyn Plus is a prescription-strength scar gel which is available as an office dispense product through dermatology practices and medical spas. Pediacyn is a pediatric dermatology and wound care product for over-the-counter use. MicrocynAH is a HOCl-based topical product that cleans, debrides and treats a range of animal wounds and infections. |
Financial Overview |
For the nine months ended 31 December 2023, Sonoma Pharmaceuticals Inc revenues decreased 9% to $9.3M. Net loss decreased 2% to $3.8M. Revenues reflect Service and Royalty segment decrease of 74% to $322K, Animal Care segment decrease of 14% to $1.7M, Latin America segment decrease of 39% to $1.1M, United States segment decrease of 13% to $2.3M. Lower net loss reflects Selling general and admin decrease of 22% to $5M (expense). |
Employees: | 9 as of Jun 2, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $0.09M as of Dec 31, 2023 |
Annual revenue (TTM): | $12.31M as of Dec 31, 2023 |
EBITDA (TTM): | -$3.97M as of Dec 31, 2023 |
Net annual income (TTM): | -$5.08M as of Dec 31, 2023 |
Free cash flow (TTM): | -$5.20M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 15,607,433 as of Feb 7, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |